Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte

James D. Weisfeld-Adams, Mark A. Morrissey, Brian M. Kirmse, Bobbie R. Salveson, Melissa P. Wasserstein, Peter J. McGuire, Sherlykutty Sunny, Jessica L. Cohen-Pfeffer, Chunli Yu, Michele Caggana, George A. Diaz

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B12 metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine β-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS. Methods: Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease. Results: Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4 μmol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing. Conclusions: It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalMolecular Genetics and Metabolism
Volume99
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Homocystinuria
Vitamin B 12
Methionine
Screening
Newborn Infant
Metabolism
propionylcarnitine
Dried Blood Spot Testing
Propionic Acidemia
Hydroxocobalamin
Gait Ataxia
Cystathionine
Failure to Thrive
Propionates
Methylmalonic acidemia
Testing
Pathology
Deterioration
Blood
Kidney

Keywords

  • cblC
  • Cobalamin
  • Methionine
  • Methylmalonic aciduria
  • Newborn screening
  • Propionylcarnitine

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. / Weisfeld-Adams, James D.; Morrissey, Mark A.; Kirmse, Brian M.; Salveson, Bobbie R.; Wasserstein, Melissa P.; McGuire, Peter J.; Sunny, Sherlykutty; Cohen-Pfeffer, Jessica L.; Yu, Chunli; Caggana, Michele; Diaz, George A.

In: Molecular Genetics and Metabolism, Vol. 99, No. 2, 02.2010, p. 116-123.

Research output: Contribution to journalArticle

Weisfeld-Adams, James D. ; Morrissey, Mark A. ; Kirmse, Brian M. ; Salveson, Bobbie R. ; Wasserstein, Melissa P. ; McGuire, Peter J. ; Sunny, Sherlykutty ; Cohen-Pfeffer, Jessica L. ; Yu, Chunli ; Caggana, Michele ; Diaz, George A. / Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. In: Molecular Genetics and Metabolism. 2010 ; Vol. 99, No. 2. pp. 116-123.
@article{d6cd5657da294ada9cfe0dc9bac31275,
title = "Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte",
abstract = "Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B12 metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine β-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS. Methods: Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease. Results: Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4 μmol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing. Conclusions: It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.",
keywords = "cblC, Cobalamin, Methionine, Methylmalonic aciduria, Newborn screening, Propionylcarnitine",
author = "Weisfeld-Adams, {James D.} and Morrissey, {Mark A.} and Kirmse, {Brian M.} and Salveson, {Bobbie R.} and Wasserstein, {Melissa P.} and McGuire, {Peter J.} and Sherlykutty Sunny and Cohen-Pfeffer, {Jessica L.} and Chunli Yu and Michele Caggana and Diaz, {George A.}",
year = "2010",
month = "2",
doi = "10.1016/j.ymgme.2009.09.008",
language = "English (US)",
volume = "99",
pages = "116--123",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte

AU - Weisfeld-Adams, James D.

AU - Morrissey, Mark A.

AU - Kirmse, Brian M.

AU - Salveson, Bobbie R.

AU - Wasserstein, Melissa P.

AU - McGuire, Peter J.

AU - Sunny, Sherlykutty

AU - Cohen-Pfeffer, Jessica L.

AU - Yu, Chunli

AU - Caggana, Michele

AU - Diaz, George A.

PY - 2010/2

Y1 - 2010/2

N2 - Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B12 metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine β-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS. Methods: Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease. Results: Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4 μmol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing. Conclusions: It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.

AB - Introduction: Combined methylmalonic aciduria and homocystinuria, cobalamin C (cblC) type, is an inherited disorder of vitamin B12 metabolism caused by mutations in MMACHC. CblC typically presents in the neonatal period with neurological deterioration, failure to thrive, cytopenias, and multisystem pathology including renal and hepatic dysfunction. Rarely, affected individuals present in adulthood with gait ataxia and cognitive decline. Treatment with hydroxocobalamin may ameliorate the clinical features of early-onset disease and prevent clinical late-onset disease. Propionic acidemia (PA), methylmalonic acidemia (MMA), and various disorders of cobalamin metabolism are characterized by elevated propionylcarnitine (C3) on newborn screening (NBS). Distinctions can be made between these disorders with secondary analyte testing. Elevated methionine is already routinely used as a NBS marker for cystathionine β-synthase deficiency. We propose that low methionine may be useful as a secondary analyte for specific detection of cbl disorders among a larger pool of infants with elevated C3 on NBS. Methods: Retrospective analysis of dried blood spot (DBS) data in patients with molecularly confirmed cblC disease. Results: Nine out of ten patients with confirmed cblC born in New York between 2005 and 2008 had methionine below 13.4 μmol/L on NBS. Elevated C3, elevated C3:C2 ratio, and low methionine were incorporated into a simple screening algorithm that can be used to improve the specificity of newborn screening programs and provide a specific and novel method of distinguishing cblC from other disorders of propionate metabolism prior to recall for confirmatory testing. Conclusions: It is anticipated that this algorithm will aid in early and specific detection of cobalamin C, D, and F diseases, with no additional expense to NBS laboratories screening for organic acidemias and classical homocystinuria.

KW - cblC

KW - Cobalamin

KW - Methionine

KW - Methylmalonic aciduria

KW - Newborn screening

KW - Propionylcarnitine

UR - http://www.scopus.com/inward/record.url?scp=73749086315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73749086315&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2009.09.008

DO - 10.1016/j.ymgme.2009.09.008

M3 - Article

C2 - 19836982

AN - SCOPUS:73749086315

VL - 99

SP - 116

EP - 123

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -